The US anti-competition regulator has fined Cephalon $1.2 billion bringing to a close a seven year old lawsuit for alleged blocking of generic competition to its blockbuster sleep-disorder drug Provigil after the expiry of its patent.
The settlement worked out by the Federal Trade Commission ensures that Cephalon, which was acquired by Teva Pharmaceutical Industries Ltd. in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers for being overcharged.
Some of the purchasers who have settled related litigation and received compensation made by Teva will now have to deposit the same in the FTC fund for equitable monetary relief, according to the terms of the settlement, which is subject to approval of the District Court Judge.
Trial in the case is scheduled to begin June 1 in the US District Court for the Eastern District of Pennsylvania.
Full content: Forbes
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI